<DOC>
	<DOC>NCT01508806</DOC>
	<brief_summary>This trial is conducted in Oceania. The aim of this trial is to assess whether dose adjustment is required for patients with renal impairment by investigating the pharmacokinetics of liraglutide in subjects with various degrees of renal impairment.</brief_summary>
	<brief_title>Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects meeting the predefined GFR (glomerular filtration rate) criteria (estimated by the Cockcroft and Gault formula) for any of the renal function groups Body Mass Index (BMI) maximum 40 kg/m^2 Known or suspected allergy to trial product(s) or related products Renal transplanted patients Haemodialysis patients Cardiac problems Uncontrolled treated/untreated hypertension History of alcoholism or drug abuse during the last 12 months Smoking of more than 10 cigarettes per day, or the equivalent for other tobacco products Habitual excessive consumption of methylxanthinecontaining beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the investigator Excessive consumption of food deviating from a normal diet as judged by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>